HIV specialist ViiV – which is majority-owned by GlaxoSmithKline – has claimed approval from the US regulator for Rukobia (fostemsavir) as a rescue therapy for heavily pre-treated adults in ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

As with other drugs, Rukobia (fostemsavir) can cause side effects, such as nausea. If you are not able to tolerate side effects of Rukobia, talk with your doctor or pharmacist. Rukobia ...

HIV sales increased 10% at CER, driven by sales of new HIV drugs — Dovato, Cabenuva, Rukobia and Apretude. GSK generates the majority of its HIV sales from its dolutegravir franchise ...

GSK reported core earnings of 59 cents per American ... Juluca rose 10% while Dovato was up 27% in the quarter. Rukobia sales rose 46% in the quarter. Sales of new long-acting medicines, Cabenuva ...